BCMA Biomarker Predicts Outcomes in Multiple Myeloma Patients

“We can find responses, and probably more importantly, progressive disease much more rapidly than we can with conventional markers,” says Dr. James Berenson, explaining the emergence of BCMA as a reliable and effective biomarker for multiple myeloma. Dr. Berenson, the Medical & Scientific Director at the Institute for Myeloma and Bone Cancer Research, also explains how a patient’s BCMA levels at the time of diagnosis can predict outcomes. Watch now to learn from a leading myeloma expert.

Key Takeaways

  • B-cell maturation antigen (BCMA) is a protein that has emerged as an effective biomarker for multiple myeloma.
  • Patients with a low level of BCMA at the time of diagnosis are likely to respond well to treatment and have positive outcomes.
  • BCMA detects disease response and progression much more rapidly than conventional markers.
© 2024 HealthCentral LLC. All rights reserved.

More on Multiple Myeloma